KIRIN-HOLDINGS
11.5.2023 07:54:33 CEST | Business Wire | Press release
Nagasaki University presented the results of a specified clinical trial on patients with COVID-19 using Lactococcus. lactis strain Plasma*1 (L.lactis Plasma, a postbiotic), researched and developed by Kirin Holdings Company, Limited (Kirin Holdings). The results of this research was presented at the 63rd Annual Scientific Meeting of the Japanese Respiratory Society on Sunday, April 30. Nagasaki University and Kirin Holdings have jointly filed a patent application for the findings of this specified clinical trial.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230510005547/en/
Specified Clinical Research Contents (Graphic: Business Wire)
1 Lactococcus lactis subsp. lactis JCM 5805 is owned by the RIKEN BioResource Research Center (https://web.brc.riken.jp/en/)
- Current status of COVID-19
Since December 2019, COVID-19 infections have repeatedly caused pandemics, infecting 676.57 million people worldwide and killing 6.88 million (as of March 10, 2023). With the emergence of Omicron variants, the number of cases in Japan has increased, and the COVID-19 has become a more familiar infectious disease. Although SARS-CoV-2 vaccines have introduced widely and patients with mild illnesses account for a large proportion of the affected population, only a limited number of drugs are available in patients with mild illnesses who are not at risk of developing severe illnesses, and treatment is mainly based on symptomatic therapy.*2 Therefore, there is eagerly awaited for an easily accessible, safe, and effective treatment for COVID-19 in the community.
- What is L. lactis strain Plasma?
L. lactis strain Plasma was discovered by Kirin in 2010 as a lactic acid bacteria that activates plasmacytoid dendritic cells (pDC), which are a leader of the immune system. Previous basic studies showed that L.lactis Plasma stimulated pDC to have a first-line defense to viral infectious diseases. Previous clinical studies have also shown that L.lactis Plasma stimulated pDC and suppress the onset of an illness from influenza virus, rotavirus, and dengue. These scientific evidence of its immune function brought L. lactis Plasma registered as the first*4 Food with Functional Claims in Japan on August 2020.
- Specified Clinical Research Contents
Based on the results of Kirin Holdings’ research on L. lactis Plasma, Nagasaki University, as a research institute with significant achievements in the field of infectious diseases, interested in L. lactis strain Plasma which may effect in relieving symptoms in patientis with COVID-19, and has decided to conduct a specified clinical trial from December 2021.
Since December 2021, Kirin Holdings has been engaged in a specific clinical research project led by Dr. Kazuko Yamamoto, a lecturer at the Department of Respiratory Medicine, Nagasaki University Hospital (currently a professor and chair at the Division of Infectious Diseases, Respiratory and Gastroenterological Medicine (First Department of Internal Medicine), University of the Ryukyus Graduate School of Medicine). This is a multicenter, double-blinded, randomized controlled trial conducted at Nagasaki University Hospital as a core facility. The efficacy and safety of 14 days oral intake of 4 hard capsules containing L. lactis Plasma (400 billion L. lactis Plasma in total) or 4 hard capsules without L. lactis Plasma (placebo) was to be evaluated*5 by having 50 patients with COVID-19 in each group.
2 Approach to Pharmacotherapy for COVID-19 Version 15.1- the Japanese Association for Infectious Diseases
3 Secrets of Immunity - Kirin's L. lactis strain Plasma Research https://health.kirin.co.jp/en/about/about.html
4 The first brand in Japan to be registered with the Consumer Affairs Agency as a food with a functional claims for immune function.
5 Yamamoto K, et al. BMJ Open 2022;12:e061172
- Specified Clinical Trial Results
1, Change in subjective symptom overall score (primary endpoint)
The results of an overall score analysis of seven subjective symptoms (Cough, Shortness of breath, fatigue, Headaches, Anosmia and Dysgeusia, Anorexia, and Chest pain) on a 4-point scale (0 points: not affected, 1 points: little effect, 2 points: affected, 3 points: severely affected) showed no difference between the two groups.
2, Anosmia and Dysgeusia (secondary endpoints) (Graph1)
The percentage of patients who scored 0 (not affected) for smell and taste dysfunction among subjective symptoms were high in the L. lactis strain Plasma group compared to placebo group after day 9.
3, Percent change in blood pDC (secondary endpoint) (Graph2)
While the placebo group showed a significant decrease in % pDC in the blood during COVID-19 clinical course, the L. lactis strain Plasma group maintained % pDC in the blood.
4, Percent change in SARS-CoV-2 viral load (secondary endpoint) (Graph3)
The L. lactis strain Plasma group showed a significant reduction of SARS-CoV-2 viral load at day 4 of treatment whereas placebo group showed reduction at day 8.
5, Safety and adverse events
No critical adverse events of safety were observed in this study.
Although this study did not show an effect on the primary endpoint, the subjective symptom total score, these results suggested that maintained pDC by the intake of L. lactis strain Plasma may have resulted in an early reduction of SARS-CoV-2 and early recovery of smell and taste dysfunction.
Nagasaki University and Kirin hope that L. lactis Plasma will become one of the new treatment or adjunctive care to patients with mild COVID-19.
About Kirin Holdings
Kirin Holdings Company, Limited is an international company that operates in the Food & Beverages domain (Food & Beverages businesses), Pharmaceuticals domain (Pharmaceuticals businesses), and Health Science domain (Health Science business), both in Japan and across the globe.
Kirin Holdings can trace its roots to Japan Brewery which was established in 1885. Japan Brewery became Kirin Brewery in 1907. Since then, the company expanded its business with fermentation and biotechnology as its core technologies, and entered the pharmaceutical business in the 1980s, all of which continue to be global growth centers. In 2007, Kirin Holdings was established as a pure holding company and is currently focusing on boosting its Health Science domain.
Under the Kirin Group Vision 2027 (KV 2027), a long-term management plan launched in 2019, the Kirin Group aims to become A global leader in CSV*, creating value across our world of Food & Beverages to Pharmaceuticals. Going forward, the Kirin Group will continue to leverage its strengths to create both social and economic value through its businesses, with the aim of achieving sustainable growth in corporate value.
* Creating Shared Value. Combined added value for consumers as well as for society at large.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230510005547/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Verlinvest to Facilitate China Resources’ Full Exit From Oatly20.11.2026 22:30:00 CET | Press release
Proposed facilitation of China Resources’ exit from Oatly requires a tender offer because of Swedish law requirements Verlinvest recommends that Oatly shareholders and holders of ADSs do not tender their shares or ADSs. Verlinvest, the global, family-backed consumer-focused evergreen investment company, today announced it has entered into an agreement to acquire China Resources Enterprise, Limited’s (“China Resources”) indirect interests in Oatly Group AB (publ) (Nasdaq: OTLY) (“Oatly”), the world’s original and largest oat drink company. The transaction builds on Verlinvest’s investment in Oatly since 2016 and reinforces its conviction in the company’s long-term potential. A change in strategic direction of state-owned enterprise China Resources informed its decision to fully exit its investment in Oatly. China Resources worked constructively with Verlinvest to identify the best path for it to do so in recognition of the complexity of their joint holding structure. Under the agreement
Picsart Opens the AI Behind Its Platform to Developers & Businesses20.11.2026 20:54:00 CET | Press release
With Picsart Platform, developers can build their own video, audio, image features using 250+ models from 30+ providers, alongside Picsart's own editing models, through one API, CLI or MCP server. Key Takeaways One bundle, four ways to build: the API, the CLI, a playground to test models, and Picsart Media Studio, an MCP server that works with compatible AI assistants. One integration for image, video, audio and text generation from 250+ models across 30+ providers, with the freedom to switch models as a product evolves. Self-serve users pay per generation at competitive, published rates. Developers get access to Picsart's proprietary editing models, like Enhance and background removal, which are only available on Picsart Platform. Picsart, the AI media production and distribution platform backed by Sequoia Capital and SoftBank Vision Fund 2, today launched Picsart Platform - a multimodal creative AI hub that gives developers the technology behind the platform used by more than 100 mil
NetJets Becomes Official Private Aviation Provider of the Hahnenkamm Races in Kitzbühel20.11.2026 18:45:00 CET | Press release
The Partnership brings together two brands committed to excellence, precision and exceptional experiences NetJets, the global leader in private aviation, is delighted to announce its newest partnership with the Hahnenkamm Races in Kitzbühel, Austria, becoming the event's Official Private Aviation Provider. The Hahnenkamm Races are among the most prestigious and celebrated events in world alpine skiing. They attract athletes, business leaders, international guests and winter sports enthusiasts from around the world. Through this partnership, NetJets and the Hahnenkamm Races are aligning two brands renowned for excellence, precision and world-class experiences. The partnership is an exciting addition to NetJets' growing portfolio of premium lifestyle and sporting partnerships, offering Owners unique opportunities to access one of Europe's most iconic winter sporting events. Alongside premium hospitality and unforgettable behind-the-scenes experiences, the collaboration will help create e
Frontgrade Technologies Help Power Critical Computing and Electronics Aboard NASA’s Roman Space Telescope20.11.2026 18:40:00 CET | Press release
Frontgrade processors and radiation-hardened microelectronics support critical spacecraft and instrument functions on NASA’s flagship astrophysics mission Frontgrade today announced that technologies from across its space electronics portfolio are supporting multiple mission-critical systems aboard NASA’s Nancy Grace Roman Space Telescope, which successfully launched on August 30, 2026. Roman is NASA’s flagship astrophysics observatory designed to investigate dark energy, discover exoplanets and explore the evolution of the universe. Its onboard electronics include radiation-hardened processors and microelectronics, providing critical processing, communications, power-management and control functions across the spacecraft. At the centre of Roman’s computing architecture are Frontgrade Gaisler’s GR740 and GR712RC processors. The GR740 radiation-hardened quad-core LEON4FT processor serves as the computing engine for the Wildcat Processor Card, used in the spacecraft’s primary and redunda
Inside Moutai House Singapore: Beyond Baijiu, A Cultural Encounter20.11.2026 16:05:00 CET | Press release
On November 13, Moutai House officially opened at Fullerton Waterboat House in Singapore. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120301288/en/ On November 13, Moutai House officially opened at Fullerton Waterboat House in Singapore. As the world’s first Moutai brand experience space built under its new SI standards, this three-storey venue brings together cultural exhibitions, baijiu tasting, distinctive dining and creative cocktails. Using Moutai as a bridge, it creates new opportunities for Chinese baijiu culture to blend with and draw inspiration from Singapore’s diverse lifestyle and cultural scene. As early as 1954, Guizhou Moutai arrived in Singapore via the Singapore River, marking its first entry into Southeast Asia, right across from Fullerton Waterboat House. 72 years later, Moutai House has found its home along the same riverbank, transforming a historic arrival into a lasting presence and turning a con
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
